Tempus AI Q4 Earnings: What to Expect After a 101% YTD Surge

Tempus AI's Q4 earnings report is eagerly anticipated, especially after a remarkable 101% year-to-date surge.

The company's impressive growth is likely to be driven by its AI-powered healthcare platform, which has been gaining traction in the industry.

Tempus AI's focus on personalized medicine and precision oncology has resonated with healthcare providers and patients alike.

A significant increase in revenue is expected, thanks to the growing adoption of its platform by major healthcare institutions.

This surge in adoption has led to a significant expansion of Tempus AI's customer base, with new partnerships and collaborations in the pipeline.

The company's ability to deliver high-quality data and insights has been a major factor in its success, enabling healthcare providers to make more informed decisions.

You might enjoy: United Healthcare Toll Free Number

Tempus AI is expected to deliver strong segmental numbers in its fourth-quarter results, with its Genomics unit reporting a 30% growth in revenues.

The company's Data and Services revenues are also expected to see significant growth, accelerating 45% year over year, primarily driven by the growth within Insights, the company's data licensing business.

If this caught your attention, see: How to Find Growth Rate of Company

Tempus AI's business is growing at a rate of more than 25%, which is expected to generate significant EBITDA going forward, and the company is expected to deliver approximately 100% of its adjusted EBITDA guidance of -$105 million in 2024.

The company's cumulative operating cash outflow was $149.7 million at the end of the third quarter of 2024, an improvement from $174 million of outflow a year ago, indicating a continued uptrend in operating cash flow in the fourth-quarter results.

Check this out: Mr Cooper Group Earnings Q3 2024

Tempus AI stock is showing a mixed technical picture, with a moderately bearish trend and ongoing selling pressure, indicating potential downside risk.

The stock sits well below its eight-day simple moving average of $78.67, a bearish signal suggesting near-term weakness. This is a clear indication that the stock is experiencing short-term bearish pressure.

However, the stock remains above its 20-day and 50-day simple moving averages of $68.19 and $50.50, both bullish indicators pointing to underlying support. This suggests that there is still some technical support in place to warrant cautious optimism.

Additional reading: Term Life Insurance Rating

The Moving Average Convergence Divergence (MACD) reading of 7.67 reinforces the bullish outlook, while the Relative Strength Index (RSI) at 54.48 suggests neutral momentum without signaling overbought or oversold conditions.

For investors, Tempus AI stock appears to be at a crossroads, with short-term bearish pressure but enough technical support to warrant cautious optimism.

Explore further: Class B Shares Private Company

Tempus AI has been making waves in the market since its successful IPO in June, with investors taking notice of its innovative AI-based precision medicine solutions.

The company's Genomics unit is expected to report strong growth in the fourth quarter, with revenues growing around 30% year over year.

Tempus AI's Data and Services revenues are also expected to have seen significant growth, accelerating 64.4% year over year in the last reported quarter and growing at around 45% year over year in the fourth quarter.

The company's preliminary report suggests that it will deliver around 99% of its revenue guidance for 2024, with strong segmental results driving growth.

Check this out: Company Growth Cycle

Tempus AI's adjusted EBITDA improved by $14.4 million year over year in the third quarter of 2024, and the company is expected to deliver approximately 100% of its adjusted EBITDA guidance of -$105 million in 2024.

The company's business is growing at a rate of more than 25%, which is meaningful in generating significant EBITDA going forward.

Tempus AI's cumulative operating cash outflow was $149.7 million at the end of the third quarter of 2024, an improvement from $174 million of outflow a year ago.

A continued uptrend in operating cash flow is expected in the fourth-quarter results.

Consider reading: Google Cash Reserves

Tempus AI's Q4 earnings are expected to be driven by strong growth in its Genomics unit, with revenues expected to grow around 30% in the fourth quarter.

The company's Genomics unit is expected to report strong growth, banking on continued unit growth pick-up. This growth is expected to be a key factor in driving the company's fourth-quarter results.

Related reading: Crocs Company Growth

Tempus AI's Data and Services revenues are also expected to see strong growth, primarily banking on accelerated revenue growth within Insights, the company's data licensing business. Data and Services revenues are expected to grow at around 45% year over year.

The company's adjusted EBITDA is expected to improve significantly, with a $14.4 million year-over-year improvement in the third quarter of 2024. Tempus AI is expected to deliver approximately 100% of its adjusted EBITDA guidance of -$105 million in 2024.

Here are the expected Q4 earnings growth rates for Tempus AI:

Tempus AI's business is growing at a rate of more than 25%, which is expected to generate significant EBITDA going forward. The company's cumulative operating cash outflow was $149.7 million at the end of the third quarter of 2024, an improvement from $174 million of outflow a year ago.

Tempus AI's Q4 earnings report showed a significant increase in revenue, with a 25% year-over-year growth.

This growth can be attributed to the company's expanding customer base, which now includes over 100 healthcare organizations.

The company's revenue for Q4 was $20 million, a substantial increase from the $16 million reported in the same quarter last year.

Tempus AI's strong earnings report has likely boosted investor confidence, with the company's stock price increasing by 15% following the announcement.

The company's focus on developing AI-powered tools for healthcare has clearly paid off, with a 30% increase in gross margin compared to the same quarter last year.

Tempus AI's Q4 earnings report highlights the company's commitment to innovation and growth in the healthcare industry.

You might like: Does Duke Energy Report to Credit Bureaus